These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21495058)

  • 1. Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.
    Graf AC; Bauer P
    Stat Med; 2011 Jun; 30(14):1637-47. PubMed ID: 21495058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.
    Graf AC; Bauer P; Glimm E; Koenig F
    Biom J; 2014 Jul; 56(4):614-30. PubMed ID: 24753160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical inference following sample size adjustment based on the 50%-conditional-power principle.
    Chen YHJ; Yuan SS; Li X
    J Biopharm Stat; 2018; 28(3):575-587. PubMed ID: 28850000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.
    Broberg P
    BMC Med Res Methodol; 2013 Jul; 13():94. PubMed ID: 23870495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient sample size adaptation strategy with adjustment of randomization ratio.
    Wang X; Xu T; Zhong S; Zhou Y; Cui L
    Biom J; 2019 May; 61(3):769-778. PubMed ID: 30650202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision of maximum likelihood estimation in adaptive designs.
    Graf AC; Gutjahr G; Brannath W
    Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculating sample size in trials using historical controls.
    Zhang S; Cao J; Ahn C
    Clin Trials; 2010 Aug; 7(4):343-53. PubMed ID: 20573638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the sample size at interim for a two-sample experiment without Type I error inflation.
    Dunnigan K; King DW
    Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation.
    Yu J; Lai D
    Contemp Clin Trials; 2019 Dec; 87():105874. PubMed ID: 31678412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size re-estimation in paired comparative diagnostic accuracy studies with a binary response.
    McCray GPJ; Titman AC; Ghaneh P; Lancaster GA
    BMC Med Res Methodol; 2017 Jul; 17(1):102. PubMed ID: 28705147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When inferiority meets non-inferiority: implications for interim analyses.
    Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
    Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.